Biomarkers can not only reveal molecular‐level mechanisms of disease development but also accurately assess early and low‐level damage, and provide early warning, prognostic evaluation, and a basis for precise staging of diseases.[214] Relevant studies have identified biomarkers associated with the diagnosis of DM‐TB, such as the HLA‐DRA‐DQA1 region rs2894257, rs3135359, and rs4733781 in genomics.[162] However, there is a lack of research on biomarkers specific to DM‐LTBI. This evidence concerns the gene HLA-DRA and diabetes mellitus.